Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 3 Interventional

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

ClinicalTrials.gov ID: NCT01762592

Public ClinicalTrials.gov record NCT01762592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

Study identification

NCT ID
NCT01762592
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 3
Lead sponsor
Heidelberg Pharma AG
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • Iodine (124I) Girentuximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2019
Last update posted
Dec 21, 2017

2017 – 2019

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
David Geffen School of Medicine, UCLA Los Angeles California 90095-1721
H. Lee Moffitt Cancer Center & Research Center Tampa Florida 33612
Lahey Clinic Burlington Massachusetts 01805
Memorial Sloan-Kettering Cancer Center New York New York 10021
Duke University Medical Center Durham North Carolina 27711
Ohio State University Columbus Ohio 43210
Fox Chase Cancer Center Philadelphia Pennsylvania 19104-4283
MD Anderson Houston Texas 77030-4009

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01762592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 21, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01762592 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →